Protalix BioTherapeutics, Inc. Common Stock (PLX) Stock Price

PLXStock

$2.62+9.17%52W

Market Cap$211.10M

P/E63.20x

PEG Ratio—

Div yield—

Beta-0.04

PLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.11%

Price vs S&P 500 (4W)-3.40%

VGM Score68.60

P/E Ratio (Annual)63.20x

P/CF (Annual)21.36x

Book Value / Share (Quarterly)$0.89

Revenue Growth (3Y)3.45%

Cash Flow / Share (Quarterly)$0.10

Price vs S&P 500 (YTD)33.63%

Gross Margin (TTM)69.20%

Net Profit Margin (TTM)23.50%

EPS (TTM)$0.23

10-Day Avg Trading Volume1.04M

EPS Excl Extra (TTM)$0.23

Revenue Growth (5Y)-3.46%

EPS (Annual)$-0.08

ROI (Annual)-13.69%

Gross Margin (Annual)48.82%

Net Profit Margin (5Y Avg)-19.52%

Cash / Share (Quarterly)$0.50

P/E Basic Excl Extra (TTM)11.14x

Revenue Growth QoQ (YoY)27.07%

P/E Normalized (Annual)63.20x

ROA (Last FY)-8.02%

Revenue Growth TTM (YoY)30.14%

EBITD / Share (TTM)$0.31

ROE (5Y Avg)70.52%

Operating Margin (TTM)28.89%

Cash Flow / Share (Annual)$-0.17

P/B Ratio2.96x

P/B Ratio (Quarterly)2.63x

Net Income / Employee (Annual)$-29,200

EV / Revenue (TTM)2.28x

Net Interest Coverage (TTM)-50.93x

ROA (TTM)20.09%

EPS Growth QoQ (YoY)2185.00%

EV / EBITDA (TTM)7.39x

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)1.91x

3-Month Avg Trading Volume0.75M

52-Week Price Return9.17%

EV / Free Cash Flow (Annual)23.22x

P/E Incl Extra (TTM)11.14x

Revenue / Employee (TTM)$356,700

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)4.00x

Asset Turnover (Annual)0.64x

52-Week High$3.19

Operating Margin (5Y Avg)-13.56%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)19.94%

26-Week Price Return11.02%

Quick Ratio (Annual)1.53x

13-Week Price Return10.08%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.94x

Enterprise Value$183.68M

Revenue / Share Growth (5Y)-20.82%

Asset Turnover (TTM)0.85x

Revenue / Employee (Annual)$233,400

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-10.63%

Cash / Share (Annual)$0.38

3-Month Return Std Dev44.05%

Gross Margin (5Y Avg)56.89%

Net Income / Employee (TTM)$83,800

ROE (Last FY)-13.69%

Net Interest Coverage (Annual)27.85x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)9.22x

Receivables Turnover (TTM)6.21x

EV / Free Cash Flow (TTM)23.95x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.23

Receivables Turnover (Annual)8.98x

ROI (TTM)31.61%

P/S Ratio (TTM)2.62x

Pretax Margin (5Y Avg)-18.38%

Revenue / Share (Annual)$0.67

Tangible BV / Share (Annual)$-0.20

Forward P/E10.92x

Price vs S&P 500 (52W)-6.37%

P/E Ratio (TTM)11.14x

EPS Growth TTM (YoY)298.24%

Year-to-Date Return45.56%

5-Day Price Return-5.76%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-11.67%

Net Profit Margin (Annual)-12.52%

Month-to-Date Return-5.07%

Cash Flow / Share (TTM)$0.18

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-10.43%

LT Debt / Equity (Annual)6.61x

P/CF (TTM)21.27x

ROI (5Y Avg)-23.85%

P/E Excl Extra (TTM)11.14x

LT Debt / Equity (Quarterly)0.52x

EPS Basic Excl Extra (TTM)$0.23

P/TBV (Quarterly)2.73x

P/B Ratio (Annual)3.00x

Inventory Turnover (TTM)0.93x

Pretax Margin (TTM)29.10%

Book Value / Share (Annual)$0.60

Price vs S&P 500 (13W)7.40%

Beta-0.04x

P/FCF (Annual)28.56x

Revenue / Share (TTM)$0.98

ROE (TTM)31.61%

52-Week Low$1.60

vGradeB

gGradeB

mGradeB

vgmGradeB

PLX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.01	$0.05	+600.00%(+$0.06)
Q1 2026	May 13, 2026	-$0.01	$0.22	+2300.00%(+$0.23)
Q4 2025	Mar 18, 2026	$0.01	-$0.07	-1500.00%(-$0.08)
Q3 2025	Nov 13, 2025	$0.06	$0.03	-45.45%(-$0.03)
Q2 2025	Aug 14, 2025	$0.03	$0.00	-100.00%(-$0.03)

PLX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PLXProtalix BioTherapeutics, Inc. Common Stock	B	B	B	2.6x	30.1%	69.2%	—	$2.62
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Protalix BioTherapeutics, Inc. Common Stock

Protalix BioTherapeutics develops recombinant therapeutic proteins using its proprietary ProCellEx platform to treat rare lysosomal storage and genetic diseases, including Gaucher disease, Fabry disease, and cystic fibrosis. Revenue comes from product sales in Brazil and a manufacturing supply agreement with Pfizer. The company's pipeline includes ELFABRIO, Uricase, and Long Acting DNase I.